LISCure Biosciences key facts
- Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer.
- It has raised $47.5M; the latest was Later Stage VC ($14.1M) in Dec 2024.
- Notable investors include KB Investment, Mayo Clinic, Yuanta Investment, Shinhan Securities, IBK Securities — 18 tracked in total.
- Status: Privately Held (backing).
Who backs LISCure Biosciences
18+Membership and data by Private Market View
- ·The complete investor list: 18 names
- ·Watch LISCure Biosciences: the Monday email on marks, rounds and moves
LISCure Biosciences funding rounds
No funding rounds for LISCure Biosciences are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
LISCure Biosciences investors
18 investors are on record for LISCure Biosciences, including KB Investment, Mayo Clinic, Yuanta Investment and Shinhan Securities.
About LISCure Biosciences
Developer of bacteria-mediated immunotherapy designed to treat tumors as well as cancer. The company's immunotherapy is used by combining drugs, consisting of seven pipelines of medicine and two pipelines of health-functioning food, enabling healthcare professionals to treat tumors as well as degenerative neurological, autoimmune and metabolic diseases.
- Sector
- Healthcare
- HQ
- Seongnam, South Korea
- Founded
- 2018
- Employees
- 30
- Website
- liscure.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
LISCure Biosciences doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.